Qualify for a free subscription to HealthLeaders magazine.
Technology: Irreversible Electroporation (IRE)
Manufacturer: AngioDynamics Inc.
Purpose: IRE technology is designed to destroy cancer cells in a manner that spares all surrounding tissue and vessels. Lesions heal in as little as two weeks compared to years for radiation therapy. It is intended to safely treat a wide range of diseases, from liver tumors to prostate cancer.
Early adopter: The Alfred in Melbourne, Australia
How The Alfred uses it: In late November 2008, doctors at the Australian teaching hospital performed the first percutaneous uses of IRE technology on liver and kidney lesions using the NanoKnife system, which causes cell death by impacting the cell membranes with electrical pulses in targeted tissue, sparing nearby nerves, blood vessels, the lymphatic system, and other delicate structures.
Potential Improvement: Unlike thermal ablation modalities like cryo-ablation, microwave, and radiofrequency ablation, which destroy all cells and critical structures in targeted tissue, IRE technology targets specific cell structures without damaging surrounding tissue.
What's Next: AngioDynamics plans to file investigational device exemptions with the Food and Drug Administration to pursue more specific tissue indications.
- How Top-Ranked MA Plans Earn Their Stars
- Readmissions: No Quick Fix to Costly Hospital Challenge
- How Hospitals Can Become 'Upstreamists'
- 4 Ways to Lower the Cost to Collect from Self-Pay Patients
- House Calls Key to Pioneer ACO Success
- How Telehealth Pays Off for Providers, Patients
- 4 Tips for Managing Employed Physicians
- Defensive Medicine Still Prevalent Despite Tort Reform
- WellPoint Dominates Nearly Half of Markets, AMA Says
- 'Overtreatment' Debate Circles Back to Lung Cancer Screening